Close Menu

NEW YORK (GenomeWeb) — LexaGene announced today that it is planning a non-brokered private placement of up to roughly C$2 million ($1.5 million) worth of stock and warrants.

Beverly, Massachusetts-based LexaGene — which trades on the Toronto Stock Exchange — said it will offer up to 3 million units at C$.65 apiece. Each unit will consist of one common share and a warrant to purchase one common share at C$.85 for a period of 15 months from the date the unit was issued.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.